Jun 6, 2026 at 2:21 PM#6
To add the structural biology perspective — how do these modifications affect receptor binding geometry?
Cryo-EM structures of GLP-1R bound to different agonists reveal the molecular basis for SAR:
Receptor binding modes:
The GLP-1R has a two-domain architecture:
1. ECD (extracellular domain): α-helical "stalk" that captures the peptide's C-terminal helix
2. TMD (transmembrane domain): 7-TM bundle that engages the peptide's N-terminus (activation domain)
Native GLP-1 binding footprint:
- C-terminal helix (residues 22-36): extensive ECD contacts (His7 Ų buried surface area)
- N-terminal region (residues 7-14): inserts into TMD core, making contacts with TM1, TM2, TM3, TM5, ECL1, ECL2
> "Cryo-EM structure of GLP-1-GLP-1R-Gs at 3.0 Å resolution revealed that the peptide N-terminus (His7-Gly10) penetrates deep into the TMD core, with His7 forming a hydrogen bond with Glu387 (TM7) and Phe12 making extensive van der Waals contacts with a hydrophobic pocket formed by Leu141 (ECL1), Tyr145 (TM2), and Trp306 (TM5)."
> — Zhang et al., *Nature*, 2017; 546:248–253
The Aib⁸ substitution: the extra methyl group of Aib fits into a small hydrophobic sub-pocket near TM1/TM2 without clashing — this is why GLP-1R potency is maintained. But at the DPP-4 active site, the same methyl group creates a steric clash with Tyr547, preventing catalysis.
This is beautiful dual-optimization: one modification simultaneously improves stability AND preserves target binding, because the DPP-4 and GLP-1R binding sites contact position 8 differently.
17 12amsterdam_pete, LondonLisa, mike_nyc and 14 others
Reply Quote Save Share Report
Jun 6, 2026 at 2:46 PM#7
Let me add the SAR for the emerging next-generation molecules:
ORFORGLIPRON (Eli Lilly, Phase 3):
This is NOT a peptide — it's a small molecule GLP-1R agonist. MW ~530 Da. This was a massive breakthrough in medicinal chemistry because achieving agonism at a Class B GPCR with a small molecule was considered nearly impossible.
Key structural features:
- Chromane core with pyrazole substituent
- Occupies the TMD orthosteric pocket (overlapping with the peptide N-terminus binding site)
- Does NOT contact the ECD — relies entirely on TMD interactions
- Oral bioavailability ~40% (no SNAC needed)
> "Orforglipron is a non-peptidic, orally bioavailable GLP-1R agonist that binds within the transmembrane domain core, making contacts with TM1, TM2, TM3, and ECL2, achieving an EC₅₀ of 2.5 nM for cAMP production — within 10-fold of native GLP-1."
> — Wunderlich et al., *Journal of Medicinal Chemistry*, 2024; 67:3199–3214
DANUGLIPRON (Pfizer, development paused/reformulated):
Another small molecule GLP-1R agonist but with different scaffold (pyrimidinedione). More biased toward Gs over β-arrestin compared to orforglipron.
The transition from peptide to small molecule agonists represents a paradigm shift in incretin drug design — but the peptide SAR was essential for identifying the critical receptor contacts that small molecule design could target.
16 11traveltech_sara, AttorneyGrant, DebRD_ATL and 13 others
Reply Quote Save Share Report
Jun 6, 2026 at 3:12 PM#8
To close this SAR overview with a comparative analysis — here's what the evolution teaches us about GLP-1R pharmacology:
Lessons learned from 30 years of GLP-1 SAR:
1. The N-terminus is the activation domain. Residues 7-14 are essential for receptor activation. Modifications here must be extremely conservative (Ala→Aib is about the limit).
2. The C-terminus is the affinity domain. Residues 22-36 can tolerate more variation. This is where acylation sites and selectivity determinants reside.
3. Helical stability matters. GLP-1 forms an α-helix in solution, and helix-stabilizing modifications (Aib, lactam bridges, stapled peptides) generally improve potency.
4. DPP-4 resistance and receptor binding are separable. Position 2/8 modifications for DPP-4 resistance don't compromise receptor binding — a fortunate structural coincidence.
5. Albumin binding transforms PK without killing PD. The linker length must be sufficient to allow simultaneous albumin and receptor binding. OEG spacers solved this problem.
> "The therapeutic evolution of GLP-1 receptor agonists from exenatide (2005) to tirzepatide (2022) represents one of the most successful applications of structure-activity relationship-guided drug design in pharmaceutical history, with each generation addressing a specific limitation of the prior molecule while preserving the core pharmacophore."
> — Drucker, *Nature Reviews Drug Discovery*, 2020; 19:529–548
The next frontier: allosteric modulators, biased agonists, and small molecules that bypass the traditional peptide pharmacophore entirely. The SAR knowledge accumulated over three decades is the foundation for all of it.
15 10patPC_UT, Dr.DermMIA, fiona_VT and 12 others
Reply Quote Save Share Report
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View Results